If You Invested in Zomedica Corp (ZOMDF)

Zomedica Corp. (ZOMDF) is an animal health company focused on equine and companion animal care. According to company disclosures, Zomedica offers point-of-care diagnostic and therapeutic device products designed to help veterinarians improve clinical outcomes, practice workflow, and financial performance. The company is headquartered in Michigan and its products are manufactured and distributed from facilities in Georgia and Minnesota.

Zomedica describes itself as an equine and companion animal healthcare company dedicated to providing veterinarians with therapeutic and diagnostic solutions. Its portfolio targets musculoskeletal healing, pain management, monitoring, and in-clinic diagnostics, with an aggregate U.S. total addressable market the company estimates at more than $2 billion.

Therapeutic device portfolio

A core element of Zomedica’s business is its therapeutic device segment. The company highlights the PulseVet shock wave system, which it characterizes as a gold standard technology that accelerates healing in musculoskeletal conditions and has transformed veterinary therapeutics. Zomedica also markets the Assisi line of therapeutic devices, including the Assisi Loop and Assisi Loop Lounge products that use targeted pulsed electromagnetic field (tPEMF) technology to reduce inflammation, relieve pain, and support healing in companion animals. The company states that Assisi devices are used by veterinarians, rehabilitation specialists, and pet parents.

Within the Assisi portfolio, Zomedica has introduced the Assisi Loop Lounge, a tPEMF therapy bed that provides full-body treatment and is positioned for use in clinics, at home, and in hospice and palliative care settings. The company notes that Assisi products are backed by peer-reviewed research and are intended as non-pharmaceutical tools for managing pain, mobility, and recovery.

Diagnostic platforms and monitoring systems

Zomedica also operates a diagnostics segment centered on its TRUFORMA in-clinic diagnostic platform. The company reports that TRUFORMA delivers point-of-care testing with reference-lab quality results, supporting faster decision-making in veterinary practices. Assays on the platform include endocrine tests such as endogenous ACTH, insulin with automatic dilution, cortisol, and an equine progesterone assay for reproductive management, as well as a multiplexed cobalamin and folate assay that has been expanded from canine to feline use.

Complementing TRUFORMA, Zomedica offers the TRUVIEW digital cytology system, which the company links to its diagnostic segment and intellectual property portfolio. Zomedica has also disclosed plans to introduce a TRUVIEW AI platform to further support diagnostic workflows.

In patient monitoring, Zomedica markets the VETGuardian Zero Touch monitoring system. The company describes VETGuardian as a no-touch or Zero Touch platform that continuously monitors vital signs without physical contact, aiming to reduce animal stress and improve staff safety and workflow efficiency. Zomedica has launched the next-generation VETGuardian PLUS monitor, which adds a built-in display, remote viewing within the clinic, live video with night vision and thermal imaging, and flexible mounting options for cages and runs. These enhancements are presented as responses to feedback from veterinary professionals.

Hemostatic and other solutions

Zomedica’s portfolio also includes VETIGEL, described by the company as a hemostatic gel that rapidly stops bleeding. VETIGEL is positioned as a hemostatic agent for veterinary use. In addition, Zomedica references EquiLoop therapeutic devices in certain equine-focused distribution agreements, further extending its therapeutic offerings for horse health.

Business segments and revenue model

Based on its public communications, Zomedica generates revenue from multiple segments. The company reports a Diagnostics segment that includes TRUFORMA, TRUVIEW, and VETGuardian products, and a Therapeutic Device segment that includes PulseVet and Assisi products. Zomedica also discloses a Development Services segment that captures revenue from development and engineering services, contract manufacturing, and licensing of its intellectual property, including work for a company in the human health space.

Within these segments, Zomedica distinguishes between consumable revenues and capital revenues. Consumables include items such as TRUFORMA assays and PulseVet trodes associated with installed systems, while capital revenues relate to device sales such as PulseVet and VETGuardian units. The company emphasizes that growth in consumable sales reinforces its recurring revenue model as more devices are installed.

Geographic reach and distribution

Zomedica states that it is expanding internationally through distribution partnerships. In Europe, the company has an expanded distribution agreement with Grovet b.v., an equine health company based in the Netherlands. Under this agreement, Grovet distributes equine therapeutic devices such as PulseVet systems, VETIGEL hemostatic gel, EquiLoop devices, and the TRUFORMA diagnostic platform for equine and companion animals across European markets.

For monitoring products, Zomedica notes that the VETGuardian PLUS monitor is available directly from the company and through veterinary product distributors in the United States and select international markets, including Patterson Veterinary Supply, Covetrus, Midwest Veterinary Supply, Pioneer Veterinary Products in the United Kingdom, and UXR Inc. in Canada. These relationships support the company’s stated strategy of leveraging regional partners to accelerate adoption of its technologies.

Operations, scale, and financial context

Zomedica reports that it employs approximately 150 people and operates what it describes as world-class manufacturing and distribution facilities in Georgia and Minnesota. The company has communicated that it grew revenue by 8% in 2024 to $27 million and has reported liquidity levels in the tens of millions of dollars as of mid and late 2025. Zomedica highlights gross margins in its financial updates and notes ongoing cost-reduction initiatives aimed at improving operating leverage.

According to a recent earnings release, Zomedica’s diagnostics segment has experienced year-over-year growth, driven by adoption of the TRUFORMA platform and an expanded assay menu, while therapeutic device revenue has been supported by PulseVet and Assisi products. The company also reports growth in international sales through distributor relationships in markets such as the United Kingdom, the Netherlands, and Canada.

Strategic focus and investor communications

Zomedica describes its strategy as advancing product offerings, leveraging strategic acquisitions, and expanding internationally to enhance the quality of care for pets, increase pet parent satisfaction, and improve veterinary practice workflow, cash flow, and profitability. The company emphasizes platform-based growth, citing scalable product platforms such as TRUFORMA, VETGuardian, and Assisi as foundations for sustainable expansion.

To communicate with investors and stakeholders, Zomedica hosts recurring webinars under its “Fourth Friday at Four” series. These sessions provide overviews of product platforms, strategic context, and business performance. The company has also scheduled special editions of the series to review quarterly results and discuss topics such as digital innovation, technology-driven growth, and the role of its monitoring and diagnostic platforms in the veterinary market.

Position within animal health and veterinary devices

Across its disclosures, Zomedica consistently positions itself as an equine and companion animal health company focused on point-of-care diagnostics, therapeutic devices, and monitoring technologies. By combining shock wave therapy, tPEMF-based devices, in-clinic diagnostic assays, digital cytology, and Zero Touch monitoring, the company aims to provide tools that support veterinarians in managing musculoskeletal conditions, pain, reproductive health, gastrointestinal disease, and general monitoring needs.

Zomedica’s stated approach includes building digital experiences and connected platforms around its products, with the goal of supporting product innovation, revenue expansion, and operating leverage. The company’s investor communications highlight ongoing development work, intellectual property protection, and regulatory considerations, as well as risks related to clinical studies, commercialization, supply chain, competition, and strategic partnerships, as further detailed in its SEC and SEDAR+ filings.